Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a
Company to present topline 40-week Phase 2 study efficacy and safety results of migaldendranib (MGB), a novel first-in-class nanomedicine for DME and nAMD Subcutaneous at-home
Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD Novel subcutaneous delivery may offer a more
Novel nanomedicine radiotracer crosses blood brain barrier in patients with neuroinflammation Tumor macrophage radiotracer achieves 41.6% peak tumor uptake in preclinical studies REDWOOD CITY, Calif.,
Company to showcase breakthrough imaging agents advancing precision medicine in neurology and oncology REDWOOD CITY, Calif., June 17, 2025 — Ashvattha Therapeutics (“Ashvattha”), a
Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current
Subcutaneous administration generally safe and well-tolerated across multiple doses >80% reduction in anti-VEGF intravitreal injection burden in wet AMD and DME study eyes and >75%
Presentations to highlight updated Phase 2 subcutaneous migaldendranib (MGB) data for wet AMD and DME REDWOOD CITY, Calif., April 15, 2025 — Ashvattha Therapeutics (“Ashvattha”),
New Clinical Advisory Board brings together distinguished retinal specialists to provide strategic guidance on development of Ashvattha’s innovative nanomedicine programs REDWOOD CITY, Calif., Mar. 18,
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in anti-VEGF IVT treatment in fellow